GHRP-6 vs Tesamorelin
Both GHRP-6 and Tesamorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRP-6
Evidence BGrowth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
View full GHRP-6 profile →Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Side-by-Side
| Attribute | GHRP-6 | Tesamorelin |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — research compound | FDA-approved for HIV-associated lipodystrophy |
| Typical Dose | 100–300 mcg, 1–3 times daily (subcutaneous) | 2 mg daily (subcutaneous) |
| Clinics Indexed | 64 | 178 |
| Categories | growth-hormone, appetite | growth-hormone, fat-loss |
Key reported benefits — GHRP-6
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.